[go: up one dir, main page]

MX2023011441A - Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. - Google Patents

Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico.

Info

Publication number
MX2023011441A
MX2023011441A MX2023011441A MX2023011441A MX2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A MX 2023011441 A MX2023011441 A MX 2023011441A
Authority
MX
Mexico
Prior art keywords
pi3k
treatment
pancreatic cancer
delta inhibitor
inhibitor
Prior art date
Application number
MX2023011441A
Other languages
English (en)
Inventor
Der Veen Lars Van
Zoë Johnson
Karolina Niewola-Staszkowska
Georgia Konstantinidou
Original Assignee
Ionctura Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2108242.5A external-priority patent/GB202108242D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura Sa filed Critical Ionctura Sa
Publication of MX2023011441A publication Critical patent/MX2023011441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un inhibidor de PI3K-delta o una sal farmacéuticamente aceptable de este para usar en un método de tratamiento del cáncer pancreático en un paciente, opcionalmente en donde el método comprende además la administración de un inhibidor de autotaxina (ATX) o una sal farmacéuticamente aceptable de este.
MX2023011441A 2021-03-29 2022-03-29 Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. MX2023011441A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2108242.5A GB202108242D0 (en) 2021-06-09 2021-06-09 Methods of treatment
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
PCT/EP2022/058296 WO2022207648A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2023011441A true MX2023011441A (es) 2023-10-18

Family

ID=81388891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011441A MX2023011441A (es) 2021-03-29 2022-03-29 Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico.

Country Status (7)

Country Link
US (1) US20240216385A1 (es)
EP (1) EP4313059A1 (es)
JP (1) JP2024511836A (es)
AU (1) AU2022250707A1 (es)
CA (1) CA3212522A1 (es)
MX (1) MX2023011441A (es)
WO (1) WO2022207648A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202108245D0 (en) * 2021-06-09 2021-07-21 Ionctura Sa Methods of treatment
GB202308807D0 (en) * 2023-06-13 2023-07-26 Ionctura Sa Combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049766A (ko) 2009-11-13 2013-05-14 메르크 세로노 에스. 에이. 트리사이클릭 피라졸 아민 유도체
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) * 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
WO2018189335A1 (en) * 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
WO2022207648A1 (en) 2022-10-06
US20240216385A1 (en) 2024-07-04
CA3212522A1 (en) 2022-10-06
AU2022250707A1 (en) 2023-10-12
JP2024511836A (ja) 2024-03-15
EP4313059A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
ZA202309638B (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
PH12022551424A1 (en) Kras g12c inhibitors.
MX2022014104A (es) Inhibidores de atr para el tratamiento del cancer.
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2020191056A8 (en) Pyridazinones and methods of use thereof
MX2023001071A (es) Tratamiento de la migraña.
ZA202401684B (en) Novel parp7 inhibitor and use thereof
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2023011441A (es) Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico.
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
MX2025001982A (es) Inhibidores de kif18a y usos de estos
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2023005806A (es) Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras).
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
MX2020011453A (es) Combinaciones para tratar el cancer.
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
PH12021552977A1 (en) Methods of treating urinary system cancers
MX2024010644A (es) Uso de iptacopan para el tratamiento de la nefritis lupica.
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment